Search results
Results From The WOW.Com Content Network
Letrozole, sold under the brand name Femara among others, is an aromatase inhibitor medication that is used in the treatment of breast cancer for post-menopausal women. [ 1 ] It was patented in 1986 and approved for medical use in 1996. [ 4 ]
Ovarian stimulation with the aromatase inhibitor letrozole has been proposed for ovulation induction in order to treat unexplained female infertility. In a multi-center study funded by the National Institute of Child Health and Development, ovarian stimulation with letrozole resulted in a significantly lower frequency of multiple gestation (i.e., twins or triplets) but also a lower frequency ...
Occasionally, this insomnia may be worse than the insomnia the drug was intended to treat. [1] Common medicines known to cause this problem are eszopiclone , zolpidem , and anxiolytics such as benzodiazepines and which are prescribed to people having difficulties falling or staying asleep.
Benzodiazepines, like many other sedative hypnotic drugs, cause apoptotic neuronal cell death. However, benzodiazepines do not cause as severe apoptosis to the developing brain as alcohol does. [105] [106] [107] The prenatal toxicity of benzodiazepines is most likely due to their effects on neurotransmitter systems, cell membranes and protein ...
Biofeedback has been shown to be an effective treatment for insomnia and is listed in the American Academy of Sleep Medicine treatment guidelines. This form of therapy includes visual or auditory feedback of e.g. EEG or EMG activity. This can help insomnia patients to control their physiological arousal. [4] [38]
Light therapy is a natural, simple, low-cost treatment that does not lead to residual effects or tolerance. Adverse reactions include headaches, eye fatigue, and even mania. [187] In addition to the cognitive behavioral treatment of insomnia, there are also generally four approaches to treating insomnia medically.
Advanced Sleep Phase Disorder (ASPD), also known as the advanced sleep-phase type (ASPT) of circadian rhythm sleep disorder, is a condition that is characterized by a recurrent pattern of early evening (e.g. 7-9 PM) sleepiness and very early morning awakening (e.g. 2-4 AM).
It is not advisable to prescribe somnifacients for routine insomnia treatment, and they should only be used for short periods in patients who are severely distressed or with transient insomnia. [40] An important drawback of prolonged use is that it can result in rebound insomnia and withdrawal syndrome upon discontinuation. [ 40 ]